eFFECTOR Therapeutics Résultats passés

Passé contrôle des critères 0/6

Les bénéfices de eFFECTOR Therapeutics ont diminué à un taux annuel moyen de -43.2%, tandis que le secteur Biotechs a vu ses bénéfices augmenter de en à 19.3% par an. Les revenus ont augmenté de en baisse à un taux moyen de 76.6% par an.

Informations clés

-43.2%

Taux de croissance des bénéfices

80.6%

Taux de croissance du BPA

Biotechs Croissance de l'industrie	17.0%
Taux de croissance des recettes	-76.6%
Rendement des fonds propres	-4,187.5%
Marge nette	n/a
Dernière mise à jour des bénéfices	31 Mar 2024

Mises à jour récentes des performances passées

Recent updates

eFFECTOR doses first patient in second cohort of phase 1b trial of potential COVID drug

Sep 14

eFFECTOR Therapeutics GAAP EPS of -$0.17

Aug 09

eFFECTOR: Developing New Class Of Cancer Therapies

Sep 12

Ventilation des recettes et des dépenses

Comment eFFECTOR Therapeutics gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.

Historique des gains et des recettes

OTCPK:EFTR Recettes, dépenses et bénéfices (USD Millions )
Date	Recettes	Les revenus	Dépenses G+A
31 Mar 24	0	-35	11
31 Dec 23	0	-36	11
30 Sep 23	1	-36	11
30 Jun 23	2	-37	12
31 Mar 23	4	-36	12
31 Dec 22	4	-23	13
30 Sep 22	3	6	16
30 Jun 22	3	24	17
31 Mar 22	1	25	16
31 Dec 21	1	16	13
30 Sep 21	1	-4	8
30 Jun 21	1	-20	5
31 Mar 21	16	-7	5
31 Dec 20	42	0	4

Des revenus de qualité: EFTR n'est actuellement pas rentable.

Augmentation de la marge bénéficiaire: EFTR n'est actuellement pas rentable.

Analyse des flux de trésorerie disponibles par rapport aux bénéfices

Analyse de la croissance passée des bénéfices

Tendance des revenus: EFTR n'est pas rentable et les pertes ont augmenté au cours des 5 dernières années à un rythme de 43.2% par an.

Accélération de la croissance: Impossible de comparer la croissance des bénéfices de EFTR au cours de l'année écoulée à sa moyenne sur 5 ans car elle n'est actuellement pas rentable

Bénéfices par rapport au secteur d'activité: EFTR n'est pas rentable, ce qui rend difficile la comparaison de sa croissance des bénéfices de l'année écoulée avec celle du secteur Biotechs ( 16.6% ).

Rendement des fonds propres

ROE élevé: EFTR a un retour sur capitaux propres négatif ( -4187.55% ), car il n'est actuellement pas rentable.

eFFECTOR Therapeutics Résultats passés

Passé contrôle des critères 0/6

Informations clés

Mises à jour récentes des performances passées

Third quarter 2023 earnings released: US$0.13 loss per share (vs US$0.23 loss in 3Q 2022)

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Third quarter 2021 earnings released: EPS US$0.53

Recent updates

eFFECTOR Therapeutics Files Form 15

eFFECTOR Therapeutics, Inc.(OTCPK:EFTR) dropped from NASDAQ Composite Index

eFFECTOR Therapeutics Provides Non-Compliance Update

eFFECTOR Therapeutics Plans to Voluntarily Request a Delisting of its Securities and Expects its Securities to be Delisted in the Near Term

eFFECTOR Therapeutics, Inc. Receives Written Notice from Nasdaq Regarding Minimum Value of Listed Securities

New major risk - Revenue and earnings growth

eFFECTOR Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

eFFECTOR Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

New major risk - Market cap size

New major risk - Share price stability

eFFECTOR Therapeutics, Inc. Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer

Price target decreased by 92% to US$22.50

New major risk - Share price stability

eFFECTOR Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $15.000003 million.

Price target increased by 90% to US$275

eFFECTOR Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $15.000003 million.

eFFECTOR Therapeutics, Inc. Announces New Positive Interim Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in Er+ Metastatic Breast Cancer Patients

eFFECTOR Therapeutics, Inc. Receives U.S. FDA Fast Track Designation for Zotatifin in Combination with Fulvestrant and Abemaciclib for Treatment of Er+/Her2- Advanced Metastatic Breast Cancer

New major risk - Shareholder dilution

Third quarter 2023 earnings released: US$0.13 loss per share (vs US$0.23 loss in 3Q 2022)

Effector Therapeutics, Inc. Announces Initiation of Dosing in an Investigator-Initiated Phase 1 Dose Escalation Trial Evaluating Tomivosertib in Patients with Relapsed/Refractory Acute Myeloid Leukemia (Aml)

eFFECTOR Therapeutics, Inc. Appoints Caroline Loewy to its Board of Directors

Price target decreased by 11% to US$6.58

eFFECTOR Therapeutics Receives Non-Compliance Notice from Nasdaq Stock Market Regarding Non-Compliance with Nasdaq's Minimum Bid Price Requirement

eFFECTOR Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $8.733186 million.

eFFECTOR Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $7.49325 million.

eFFECTOR Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $7.49325 million.

Price target increased by 17% to US$7.38

eFFECTOR Therapeutics Receives Non-Compliance Notice from Nasdaq

eFFECTOR Therapeutics, Inc., Annual General Meeting, Jun 22, 2023

Price target increased by 16% to US$6.33

eFFECTOR Therapeutics, Inc. Provides Positive Clinical Data Update for Zotatifin and General Corporate Update

Price target decreased to US$8.60

Price target increased to US$10.75

High number of new directors

Effector Therapeutics Completes Enrollment in Second of Three Cohorts of Phase 1B Clinical Trial of Zotatifin for the Treatment of Covid-19

Effector Therapeutics Appoints Mayank Gandhi, M.D., as Chief Business Officer

eFFECTOR Therapeutics, Inc. Doses First Patient in Second Cohort of Phase 1B Clinical Trial of Zotatifin for the Treatment of Covid-19

eFFECTOR doses first patient in second cohort of phase 1b trial of potential COVID drug

eFFECTOR Therapeutics Receives A Letter from the Nasdaq Stock Market Staff

Consensus forecasts updated

Price target decreased to US$10.68

eFFECTOR Therapeutics GAAP EPS of -$0.17

eFFECTOR Therapeutics Appoints Douglas Warner as Chief Medical Officer

eFFECTOR Therapeutics, Inc. Announces Executive Changes

Investor sentiment deteriorated over the past week

eFFECTOR Therapeutics, Inc. Reports Positive Interim Results in Zotatifin (eFT226) Phase 1/2 Clinical Trial at ASCO 2022 Showing Safety and Tolerability, and Initial Signals of Clinical Activity

Investor sentiment improved over the past week

eFFECTOR Therapeutics, Inc. Announces Interim Data from Its Ongoing Phase 1/2 Clinical Trial of Zotatifin in Solid Tumors

Consensus forecasts updated

Investor sentiment deteriorated over the past week

High number of new directors

eFFECTOR Therapeutics, Inc., Annual General Meeting, Jun 09, 2022

eFFECTOR Therapeutics, Inc. Announces Transition in Clinical Leadership

Consensus forecasts updated

Investor sentiment improved over the past week

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

eFFECTOR Therapeutics, Inc. Announces Directorate Changes

eFFECTOR Therapeutics, Inc. Provides Pipeline and Business Updates

High number of new directors

Independent Director recently sold US$475k worth of stock

eFFECTOR Therapeutics, Inc. Announces Publication of Zotatifin Preclinical Data in Frontiers in Oncology

Independent Director recently sold US$407k worth of stock

Independent Director recently sold US$222k worth of stock

Independent Director recently sold US$917k worth of stock

Third quarter 2021 earnings released: EPS US$0.53

eFFECTOR: Developing New Class Of Cancer Therapies

Ventilation des recettes et des dépenses

Historique des gains et des recettes

Analyse des flux de trésorerie disponibles par rapport aux bénéfices

Analyse de la croissance passée des bénéfices

Rendement des fonds propres